Concepedia

Author

Hiroto Fukushima

Taiho Pharmaceutical (Japan)ORCID

Also Known As

Fukushima, Hiroto, H Fukushima, H. Fukushima, Hiroto Fukushima, Hiroto S Fukushima, Hiroto S. Fukushima

33

Publications

265

Citations

8

H-Index

18

Concepts

All Affiliations

Taiho Pharmaceutical (Japan)Kurume UniversityKyoto Pharmaceutical UniversityThe University of Tokyo
HF

About

Hiroto Fukushima is an author at Taiho Pharmaceutical (Japan) specializing in medicine, pharmacology, and tumor biology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

81

2

Health Sciences

1

1

60

3

Biochemistry

1

1

60

4

Cell Biology

1

1

21

5

Metabolism

1

1

60

Hiroto Fukushima

×

8

Publications

227

Citations

8

H-Index

YearCitations

In Vivo Effects of Cyclosporin A and Ketoconazole on the Pharmacokinetics of Representative Substrates for P-Glycoprotein and Cytochrome P450 (CYP) 3A in Rats

Michiharu Kageyama, Hitomi Namiki, Hiroto Fukushima,

Biological and Pharmaceutical Bulletin

2005

60

Effect of Chronic Administration of Ritonavir on Function of Cytochrome P450 3A and P-Glycoprotein in Rats

Michiharu Kageyama, Hitomi Namiki, Hiroto Fukushima,

Biological and Pharmaceutical Bulletin

2005

45

Targeted in vivo epigenome editing of H3K27me3

Hiroto Fukushima, Hiroyuki Takeda, Ryohei Nakamura

Epigenetics & Chromatin

2019

35

TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways

Akihiro Miura, Hiroshi Sootome, Naoya Fujita,

Investigational New Drugs

2021

21

Incomplete erasure of histone marks during epigenetic reprogramming in medaka early development

Hiroto Fukushima, Hiroyuki Takeda, Ryohei Nakamura

Genome Research

2023

19

ARHGEF15 overexpression worsens the prognosis in patients with pancreatic ductal adenocarcinoma through enhancing the motility and proliferative activity of the cancer cells

Hiroto Fukushima, Makiko Yasumoto, Sachiko Ogasawara,

Molecular Cancer

2016

17

Malic enzyme 1 is a potential marker of combined hepatocellular cholangiocarcinoma, subtype with stem‐cell features, intermediate‐cell type

Yutaro Mihara, Jun Akiba, Sachiko Ogasawara,

Hepatology Research

2019

16

Alteration of dihydropyrimidine dehydrogenase expression by IFN-α affects the antiproliferative effects of 5-fluorouracil in human hepatocellular carcinoma cells

Shinji Oie, Mayumi Ono, Hiroto Fukushima,

Molecular Cancer Therapeutics

2007

14

Page 1